ABBVIE LTD

Wholesale of pharmaceutical goods

Information

Name

ABBVIE LTD

Type

Wholesale of pharmaceutical goods

Roles

Supplier

Company Size

Large

Company Number

08004972

Incorporation Date

2012-03-23 00:00:00

Website

http://www.abbvie.co.uk

Address

Abbvie House, Vanwall Business Park

Maidenhead
SL6 4UB
United Kingdom

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with ABBVIE LTD
Sign up free

Contracts awarded to ABBVIE LTD

The contracts that ABBVIE LTD have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 7 months ago

NHS National Generic Pharmaceuticals Wave 14c

NHS National Generic Pharmaceuticals- Wave 14c Offer reference number: CM/PHG/22/5672 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Orals (plus non-parenteral) Products: All Regions (CESW/LSNE/NWLN):01/06/2024 to 31/05/2027 (36 Months) Hospital Only Products: DLS & DNE: 01/06/2024 to 31/05/2026(24 months) Hospital Only Products(Housekeeping): DLN & DNW: 01/06/2024 to 31/01/2025(8 months) DCE & DSW: 01/06/2024 to 30/09/2025(16 months)

£219
Award

Published 8 months ago

NP49124 Hepatitis C Medicines

Supply of Hepatitis C Medicines to NHS Scotland.

£36,556,082
Award

Published 8 months ago

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

Project Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024 Offer reference number: CM/PHR/22/5678 CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months

£74
Award

Published 8 months ago

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

Project Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024 Offer reference number: CM/PHR/22/5678 CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

£580,156,000 Bids close: 1 year ago
Award

Published 9 months ago

Generic, Branded Generic & Proprietary Medicinal Products - Group 13

Generic, Branded Generic & Proprietary Medicinal Products - Group 13 (4844244)

£13,838,930
Award

Published 9 months ago

NP47923a Adalimumab

Supply of adalimumab to NHS Scotland.

£44,618,492

Contacts

+44 7775116875

[email protected]

View all 3 contacts, free!

Statistics (1 Year)

Contracts Won

Total Won

£106,842,019

Average Win

£21,368,404

ABBVIE LTD

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to ABBVIE LTD

NHS National Generic Pharmaceuticals Wave 14c

NP49124 Hepatitis C Medicines

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

Generic, Branded Generic & Proprietary Medicinal Products - Group 13

NP47923a Adalimumab

Contacts

Statistics (1 Year)

Contracts Won

Total Won

Average Win